Dr. Takeshima@Web

    Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al.  A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.  Expert Opinion on Drug Safety. 2022:1-8.  

    Kikui S, Chen Y, Ikeda K, Hasebe M, Asao K, Takeshima T.  Comorbidities in patients with migraine in Japan: a cross-sectional study using data from National Health and Wellness Survey.  BMJ Open. 2022;12(11):e065787. https://www.ncbi.nlm.nih.gov/pubmed/36450434 https://bmjopen.bmj.com/content/bmjopen/12/11/e065787.full.pdf 2022/12/01

  Takeshima T, Komori M, Tanji Y, Ozeki A, Tatsuoka Y.  Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.  Adv Ther. 2022;39(11):5274-88. https://www.ncbi.nlm.nih.gov/pubmed/36138260 2022/09/23

 Sakai F, Hirata K, Igarashi H, Takeshima T, Nakayama T, Sano H, et al.  A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan.  J Headache Pain. 2022;23(1):70. https://www.ncbi.nlm.nih.gov/pubmed/35733104 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219245/pdf/10194_2022_Article_1439.pdf 2022/06/23  

      Danno D, Wolf J, Ishizaki K, Kikui S, Hirata K, Takeshima T.  Cranial autonomic symptoms in migraine are related to central sensitization: a prospective study of 164 migraine patients at a tertiary headache center.  BMC Neurol. 2022;22(1):89. https://www.ncbi.nlm.nih.gov/pubmed/35287610 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919542/pdf/12883_2022_Article_2610.pdf 2022/03/16

  Oda I, Danno D, Saigoh K, Wolf J, Kawashita N, Hirano M, Samukawa M,Kitamura S, Kikui S,Takeshima T, Mitsui Y,Kusunoki S,Nagai Y Hemiplegic migraine type 2 with new mutation of the ATP1A2 gene in Japanese cases.  Neurosci Res. 2022;180:83-9. https://www.ncbi.nlm.nih.gov/pubmed/35257835 2022/03/09

   Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, et al.  Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.  Brain Behav. 2022;12(3):e2526. https://www.ncbi.nlm.nih.gov/pubmed/35201674 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933787/pdf/BRB3-12-e2526.pdf 2022/02/25

      Takeshima T , Nakai M, Shibasaki Y, Ishida M, Kim BK, Ning X, et al.  Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.  J Headache Pain. 2022;23(1):24. https://www.ncbi.nlm.nih.gov/pubmed/35139816 2022/02/11

    Takahashi M, Shimokawa T, Koh J, Takeshima T, Yamashita H, Kajimoto Y, et al.  Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan.  J Neurol Sci. 2022;432:120078. https://www.ncbi.nlm.nih.gov/pubmed/34923334 2021/12/20